China's New Drug Tech Exports Hit Record High Amid U.S. Scrutiny

China's pharmaceutical industry is experiencing explosive growth in international technology exports, reaching a record $110 billion in the first half of 2026. This surge is fueled by significant investments in cutting-edge drug development platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and immuno-oncology treatments.

Recent high-profile deals underscore this trend. AstraZeneca acquired the global development and commercialization rights for four obesity drug candidates from China's CSPC for $18.5 billion. Eli Lilly partnered with Innovent Biologics for $8.85 billion to develop and commercialize tumor and immunology-targeted antibody platforms. AbbVie also secured exclusive global rights for a bispecific antibody candidate for $5.6 billion.

Data indicates a dramatic upward trajectory: China's pharmaceutical technology exports climbed from $13.9 billion in 2021 to an estimated $41.5 billion in 2024, with projections reaching $135.7 billion to $137.7 billion in 2025. This rapid expansion is attributed to Chinese companies focusing on next-generation drug technologies and the global race among major pharmaceutical firms to secure new blockbusters as existing patents expire.

However, this remarkable growth is drawing increased attention and potential policy responses from the United States. Washington views China's burgeoning biopharmaceutical sector as a strategic threat, citing concerns over drug supply chain security, economic competitiveness, and national security. The U.S. is signaling a move towards strengthening regulations, potentially impacting the global drug development ecosystem.

Analysts predict that the interplay between U.S. and Chinese ambitions will be a major variable in the future of global drug development. This dynamic could lead to shifts in how major international pharmaceutical companies manage their pipelines and may create opportunities for neighboring countries like South Korea in areas such as contract development and manufacturing (CDMO) and technology transfer.